FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma

(June 19, 2017)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with afinitor® (everolimus), for the treatment of patients with metastatic renal cell carcinoma who have received 2 or more prior lines of therapy. ... Continue Reading

Dalantercept- Inlyta Shows Promise for Renal Cell Cancer

(March 1, 2017)

The combination of Inlyta (axitinib) and dalantercept, an activin receptor–like kinase 1 (ALK1) signaling inhibitor appears promising in the treatment of advanced renal cell carcinoma (RCC) according to the results of a recently published Phase I clinical... Continue Reading

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer

(December 5, 2016)

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results were recently published in the Journal of Clinical... Continue Reading

Lenvima® Approved for Kidney Cancer

(May 24, 2016)

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received at least one prior therapy with an anti-angiogenic... Continue Reading

Cabometyx® Approved for Kidney Cancer

(May 10, 2016)

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already... Continue Reading

Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide

(March 15, 2016)

If you are battling kidney cancer, otherwise known as renal cell carcinoma (RCC), The DART Study may be the next treatment option for you to consider. Dalantercept, in combination with axitinib, an FDA approved therapy, aims to halt the growth and... Continue Reading

FDA Approves Opdivo for Renal Cell Carcinoma

(November 25, 2015)

The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600 mutation as well as advanced non-small cell lung... Continue Reading

COMETRIQ® Improves Progression-Free Survival in Kidney Cancer

(October 15, 2015)

According to a recently published study in the New England Journal of Medicine, the targeted agent, COMETRIQ® (cabozantinib), significantly improves the time to cancer progression and survival compared to Afinitor® (everolimus) in patients with advanced... Continue Reading

Opdivo® Improves Survival in Kidney Cancer

(October 12, 2015)

The immunotherapy agent, Opdivo® (nivolumab), improves survival in kidney cancer compared to the standard treatment, Afinitor® (everolimus). These results were recently published in the New England Journal of Medicine. About Renal Cell Carcinoma Each... Continue Reading

Study of Opdivo® versus Afinitor® Stopped Early when Opdivo Demonstrated Better Survival

(July 29, 2015)

Patients with advanced or metastatic kidney cancer who are treated with Opdivo® (nivolumab) have better overall survival than those treated with Afinitor® (everolimus), according to findings from a Phase III clinical trial. Because the improved survival... Continue Reading